aspirin has been researched along with Intermittent Claudication in 80 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Blood samples were collected from 209 patients with intermittent claudication on daily aspirin therapy." | 7.91 | Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. ( Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2019) |
| "Data from 67 patients with intermittent claudication taking part in a randomised controlled trial and who received clopidogrel in addition to aspirin was analysed." | 7.73 | Variability in responsiveness to clopidogrel in patients with intermittent claudication. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2006) |
| "The main aim of medical treatment for intermittent claudication (IC) is the reduction of mortality and morbidity from ischemic cardiovascular disease." | 6.69 | Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopath ( Di Sante, G; Gresele, P; Migliacci, R; Nenci, GG, 2000) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "A total of 335 patients (206 men; mean age 72+/-9 years) with intermittent claudication were randomized according to a 2x2 factorial design to 1 of the 4 groups: probucol, placebo, EVBT, and EVBT+probucol." | 5.11 | Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. ( Alerci, M; Amann-Vesti, B; Aschwanden, M; Baumgartner, I; Bernier, J; Canevascini, R; Cozzi, L; Do, DD; Gallino, A; Greiner, R; Jacob, AL; Jäger, K; Kann, R; Kellner, F; Mahler, F; Schneider, E; Segatto, JM; Studer, G; Triller, J; Tutta, P, 2004) |
| " The aim of this study was to determine whether combination of aspirin and clopidogrel affects thrombin-antithrombin III and D-dimer in patients with intermittent claudication undergoing angioplasty, compared with aspirin alone." | 5.11 | Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2005) |
| "Indobufen--an inhibitor of platelets aggregation--has been used in 306 patients with intermittent claudication due to peripheral vascular disease." | 5.07 | Long-term evaluation of indobufen in peripheral vascular disease. ( Belcaro, G; De Simone, P, 1991) |
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "Blood samples were collected from 209 patients with intermittent claudication on daily aspirin therapy." | 3.91 | Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. ( Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2019) |
| "Blood samples were collected from 50 healthy blood donors without antithrombotic medication and 50 patients with intermittent claudication on daily aspirin therapy." | 3.83 | Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. ( Binderup, HG; Brasen, CL; Houlind, K; Madsen, JS, 2016) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| "Data from 67 patients with intermittent claudication taking part in a randomised controlled trial and who received clopidogrel in addition to aspirin was analysed." | 3.73 | Variability in responsiveness to clopidogrel in patients with intermittent claudication. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2006) |
| "Aspirin and placebo treatment were associated with elevated P-selectin expression, platelet-monocyte aggregation and reduced CD42b expression (p<0." | 2.74 | Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. ( Ashour, H; Bhattacharya, V; Cleanthis, M; Smout, J; Stansby, G, 2009) |
| "The main aim of medical treatment for intermittent claudication (IC) is the reduction of mortality and morbidity from ischemic cardiovascular disease." | 2.69 | Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopath ( Di Sante, G; Gresele, P; Migliacci, R; Nenci, GG, 2000) |
| "For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5)." | 2.52 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. ( Acosta, S; Bedenis, R; Lethaby, A; Maxwell, H; Prins, MH, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| "Peripheral arterial disease is a manifestation of systemic atherosclerosis and is predictive of future cardiovascular events." | 1.38 | The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. ( Ardati, AK; Aronow, HD; Bove, PG; Grossman, PM; Gurm, HS; Kaufman, SR; Nypaver, TJ, 2012) |
| " Balloon angioplasty with, or without stent deployment appears to be a safe procedure with excellent primary success rate." | 1.37 | [Percutaneous, endovascular treatment of innominate artery lesions is a safe and effective procedure]. ( Bérczi, V; Hüttl, K; Nemes, B; Paukovits, TM, 2011) |
| "Aspirin resistance was defined as closure time (CT) less than the upper limit of normal (158 s collagen/epinephrine agonist; 118 s collagen/adenosine diphosphate (ADP) agonist)." | 1.33 | Point of care testing of aspirin resistance in patients with vascular disease. ( Appleberg, M; Lewis, DR; Ward, CM; Wong, S, 2006) |
| "If intermittent claudication is present, angiography of the pelvis and legs then follows." | 1.31 | [Peripheral arterial occlusive disease. Symptoms, basic diagnosis and staged therapy]. ( Grothe, A; Kettmann, R; Welter, HF, 2002) |
| "Heparin-associated thrombocytopenia is mediated through IgG or IgM immunoglobulin fractions and is believed to be an immune phenomenon, with heparin acting as a hapten." | 1.27 | Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. ( Nand, S; Robinson, JA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (18.75) | 18.7374 |
| 1990's | 12 (15.00) | 18.2507 |
| 2000's | 36 (45.00) | 29.6817 |
| 2010's | 15 (18.75) | 24.3611 |
| 2020's | 2 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Espinola-Klein, C | 1 |
| Mehta, A | 1 |
| Sperling, LS | 1 |
| Wells, BJ | 1 |
| Binderup, HG | 2 |
| Houlind, K | 2 |
| Brasen, CL | 2 |
| Madsen, JS | 2 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Bedenis, R | 1 |
| Lethaby, A | 1 |
| Maxwell, H | 1 |
| Acosta, S | 1 |
| Prins, MH | 1 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Gary, T | 1 |
| Prüller, F | 1 |
| Raggam, R | 1 |
| Mahla, E | 1 |
| Eller, P | 1 |
| Hafner, F | 1 |
| Brodmann, M | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Soden, PA | 1 |
| Zettervall, SL | 1 |
| Ultee, KH | 1 |
| Landon, BE | 1 |
| O'Malley, AJ | 1 |
| Goodney, PP | 1 |
| DeMartino, RR | 1 |
| Arya, S | 1 |
| Schermerhorn, ML | 1 |
| Cleanthis, M | 3 |
| Bhattacharya, V | 3 |
| Smout, J | 2 |
| Ashour, H | 3 |
| Stansby, G | 4 |
| Tsai, TY | 1 |
| Massasso, D | 1 |
| Sharma, P | 1 |
| Crozier, J | 1 |
| Tryniszewski, W | 1 |
| Nowak, D | 1 |
| Brocki, M | 1 |
| Maziarz, Z | 1 |
| Rysz, J | 1 |
| Paukovits, TM | 1 |
| Nemes, B | 1 |
| Hüttl, K | 1 |
| Bérczi, V | 1 |
| Van Hattum, ES | 1 |
| Tangelder, MJ | 1 |
| Lawson, JA | 1 |
| Moll, FL | 1 |
| Algra, A | 1 |
| Gresele, P | 4 |
| Migliacci, R | 4 |
| Arosio, E | 2 |
| Bonizzoni, E | 2 |
| Minuz, P | 1 |
| Violi, F | 2 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Ardati, AK | 1 |
| Kaufman, SR | 1 |
| Aronow, HD | 1 |
| Nypaver, TJ | 1 |
| Bove, PG | 1 |
| Gurm, HS | 1 |
| Grossman, PM | 1 |
| Welter, HF | 1 |
| Kettmann, R | 1 |
| Grothe, A | 1 |
| Olin, JW | 1 |
| Emmerich, J | 1 |
| McDermott, MM | 1 |
| Guralnik, JM | 1 |
| Greenland, P | 1 |
| Pearce, WH | 1 |
| Criqui, MH | 1 |
| Liu, K | 1 |
| Taylor, L | 1 |
| Chan, C | 1 |
| Sharma, L | 1 |
| Schneider, JR | 1 |
| Ridker, PM | 2 |
| Green, D | 2 |
| Quann, M | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 3 |
| Fiotti, N | 1 |
| Altamura, N | 1 |
| Cappelli, C | 1 |
| Schillan, M | 1 |
| Guarnieri, G | 1 |
| Giansante, C | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 2 |
| Schmieder, FA | 1 |
| Throm, RC | 1 |
| Gaughan, JP | 1 |
| Rao, AK | 1 |
| Barlas, S | 1 |
| Tansel, T | 1 |
| Clagett, GP | 2 |
| Sobel, M | 1 |
| Jackson, MR | 2 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Cassar, K | 3 |
| Ford, I | 3 |
| Greaves, M | 3 |
| Bachoo, P | 3 |
| Brittenden, J | 3 |
| Gallino, A | 1 |
| Do, DD | 1 |
| Alerci, M | 1 |
| Baumgartner, I | 1 |
| Cozzi, L | 1 |
| Segatto, JM | 1 |
| Bernier, J | 1 |
| Tutta, P | 1 |
| Kellner, F | 1 |
| Triller, J | 1 |
| Schneider, E | 2 |
| Amann-Vesti, B | 1 |
| Studer, G | 1 |
| Jäger, K | 1 |
| Aschwanden, M | 1 |
| Canevascini, R | 1 |
| Jacob, AL | 1 |
| Kann, R | 1 |
| Greiner, R | 1 |
| Delis, KT | 2 |
| Nicolaides, AN | 2 |
| Ramaswami, G | 1 |
| D'Ayala, M | 1 |
| Hollier, LH | 1 |
| Deutsch, R | 1 |
| McElhinney, AJ | 1 |
| Shenton, B | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Hiatt, WR | 1 |
| Krantz, MJ | 1 |
| Singer, E | 1 |
| Imfeld, S | 1 |
| Hoffmann, U | 1 |
| Buschmann, I | 1 |
| Labs, KH | 1 |
| Jaeger, KA | 1 |
| Wong, S | 1 |
| Ward, CM | 1 |
| Appleberg, M | 1 |
| Lewis, DR | 1 |
| Koppensteiner, R | 2 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| van der Loo, B | 1 |
| Suvorava, T | 1 |
| Kojda, G | 1 |
| Procacci, A | 1 |
| De Monte, P | 1 |
| Dregelid, E | 1 |
| McCaslin, J | 1 |
| Daly, A | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Andreozzi, GM | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Heidrich, H | 1 |
| Vittoria, A | 1 |
| Guerrini, M | 1 |
| Pieragalli, D | 1 |
| Del Bigo, C | 1 |
| Martelli, G | 1 |
| Franchi, M | 1 |
| Messa, G | 1 |
| Blardi, P | 1 |
| Galigani, C | 1 |
| Di Perri, T | 1 |
| Bollinger, A | 1 |
| Biland, L | 1 |
| Brunner, U | 1 |
| Kappert, A | 1 |
| Krähenbühl, B | 2 |
| Monti, M | 2 |
| Nachbur, B | 1 |
| Widmer, LK | 1 |
| Freiman, DB | 1 |
| Spence, R | 1 |
| Gatenby, R | 1 |
| Gertner, M | 1 |
| Roberts, B | 1 |
| Berkowitz, HD | 1 |
| Ring, EJ | 1 |
| Oleaga, JA | 1 |
| Kohler, TR | 1 |
| Kaufman, JL | 1 |
| Kacoyanis, G | 1 |
| Clowes, A | 1 |
| Donaldson, MC | 1 |
| Kelly, E | 1 |
| Skillman, J | 1 |
| Couch, NP | 1 |
| Whittemore, AD | 1 |
| Mannick, JA | 1 |
| Heinrich, F | 1 |
| Verstraete, M | 1 |
| Kucuk, O | 1 |
| Haring, O | 1 |
| Dyer, A | 1 |
| Dormandy, JA | 1 |
| Skaria, AM | 1 |
| Hauser, C | 1 |
| Allegra, C | 1 |
| Pollari, G | 1 |
| Carioti, B | 1 |
| Sardina, M | 1 |
| Whyman, MR | 2 |
| Fowkes, FG | 2 |
| Kerracher, EM | 2 |
| Gillespie, IN | 2 |
| Lee, AJ | 2 |
| Housley, E | 2 |
| Ruckley, CV | 2 |
| Ciocon, JO | 1 |
| Galindo-Ciocon, D | 1 |
| Galindo, DJ | 1 |
| Mueller, MR | 1 |
| Salat, A | 1 |
| Stangl, P | 1 |
| Murabito, M | 1 |
| Pulaki, S | 1 |
| Boehm, D | 1 |
| Ergun, E | 1 |
| Mittlboeck, M | 1 |
| Schreiner, W | 1 |
| Losert, U | 1 |
| Wolner, E | 1 |
| Cushman, M | 1 |
| Stampfer, MJ | 1 |
| Tracy, RP | 1 |
| Hennekens, CH | 1 |
| Eccles, M | 1 |
| Freemantle, N | 1 |
| Mason, J | 1 |
| Balsano, F | 1 |
| Wolfe, JH | 1 |
| Frangos, SG | 1 |
| Chen, AH | 1 |
| Sumpio, B | 1 |
| Di Sante, G | 1 |
| Nenci, GG | 1 |
| Vass, A | 1 |
| Leng, G | 1 |
| Papacosta, O | 1 |
| Walker, M | 1 |
| Lennon, L | 1 |
| Whincup, PH | 1 |
| Johnson, WC | 1 |
| Williford, WO | 1 |
| Valentine, RJ | 1 |
| Donnelly, R | 1 |
| Yeung, JM | 1 |
| Mannarino, E | 1 |
| Pasqualini, L | 1 |
| Innocente, S | 1 |
| Scricciolo, V | 1 |
| Rignanese, A | 1 |
| Ciuffetti, G | 1 |
| Belcaro, G | 1 |
| De Simone, P | 1 |
| Nand, S | 1 |
| Robinson, JA | 1 |
| Libretti, A | 2 |
| Catalano, M | 2 |
| Zeitler, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| [NCT00035776] | 0 participants | Observational | 2001-01-31 | Completed | |||
| THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665] | 30 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
15 reviews available for aspirin and Intermittent Claudication
| Article | Year |
|---|---|
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Topics: Anastomosis, Surgical; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vas | 2015 |
Management of patients with intermittent claudication.
Topics: Aspirin; Blood Vessel Prosthesis; Cilostazol; Clopidogrel; Exercise Therapy; Humans; Intermittent Cl | 2002 |
[Thrombosis and antithrombotic agents in peripheral artery disease].
Topics: Administration, Oral; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Intermittent Claudicatio | 2002 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.
Topics: Aspirin; Bleeding Time; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Intermittent Claudication; | 2006 |
[Peripheral arterial occlusions. Principles, possibilities and limits of conservative therapy].
Topics: Ancrod; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiomyopathies; Dextrans; Digitalis | 1981 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Disease Progression; Humans; Intermittent Claud | 1994 |
Vascular drugs in the new millennium.
Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa | 2000 |
What can I do to continue walking despite intermittent claudication?
Topics: Aspirin; Cilostazol; Clopidogrel; Humans; Intermittent Claudication; Tetrazoles; Ticlopidine; Vasodi | 2001 |
Management of intermittent claudication: the importance of secondary prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Blood Pressure; Coronary Disease; | 2002 |
[Primary prevention of intermittent claudication and frequently associated arteriopathies].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Coronary Disease; Diet; Humans; Hypercholesterolemia; Hyp | 1987 |
29 trials available for aspirin and Intermittent Claudication
| Article | Year |
|---|---|
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Cilostazol; Cross-Over St | 2009 |
Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
Topics: Aged; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Double-Blind Method; Drug Administra | 2012 |
Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Ankle; Arterial Occlusi | 2003 |
Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Female; Follow-Up | 2003 |
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co | 2003 |
Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, | 2005 |
Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon; Arterial Occlusive Diseases; As | 2004 |
Effect of intermittent pneumatic compression of foot and calf on walking distance, hemodynamics, and quality of life in patients with arterial claudication: a prospective randomized controlled study with 1-year follow-up.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Flow Velocity; Exercise Test; Female; Follow-Up Studies; Foo | 2005 |
Rapid foot and calf compression increases walking distance in patients with intermittent claudication: results of a randomized study.
Topics: Administration, Oral; Aged; Aspirin; Disease Progression; Exercise Test; Follow-Up Studies; Humans; | 2005 |
Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Ster | 2005 |
Aspirin in peripheral arterial disease: breakthrough or pitfall?
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Collateral Circulation; Combined Modality Therapy | 2006 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.
Topics: Aged; Aspirin; Blood Flow Velocity; Brachial Artery; Endothelium, Vascular; Exercise; Female; Humans | 2007 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
The factor VIII complex in atherosclerosis: effects of aspirin.
Topics: Adult; Aged; Antigens; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Factor VIII; Female; Hum | 1981 |
Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
Topics: Administration, Oral; Aged; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Exercise Test; Fe | 1994 |
Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication.
Topics: Angioplasty, Balloon; Aspirin; Blood Pressure; Exercise Test; Exercise Tolerance; Female; Femoral Ar | 1996 |
A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly.
Topics: Aged; Aspirin; Female; Humans; Intermittent Claudication; Male; Pentoxifylline; Peripheral Vascular | 1997 |
Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty.
Topics: Administration, Oral; Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Blood Platel | 1997 |
Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial.
Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Blood Flow Velocity; Blood Pressure; Exercise Therapy; E | 1997 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Topics: Aged; Aged, 80 and over; Ankle; Aspirin; Blood Pressure; Brachial Artery; Case-Control Studies; Chi- | 2000 |
Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopath
Topics: Adult; Aged; Aspirin; Chromonar; Double-Blind Method; Drug Therapy, Combination; Emotions; Exercise | 2000 |
The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial.
Topics: Aged; Amputation, Surgical; Anticoagulants; Aspirin; Boston; Femoral Vein; Fibrinolytic Agents; Foll | 2002 |
Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined?
Topics: Aspirin; Combined Modality Therapy; Dipyridamole; Exercise Therapy; Female; Humans; Intermittent Cla | 1991 |
Long-term evaluation of indobufen in peripheral vascular disease.
Topics: Aspirin; Diabetes Complications; Female; Humans; Intermittent Claudication; Isoindoles; Male; Middle | 1991 |
Treatment of claudication with dipyridamole and aspirin.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therapy, Com | 1986 |
Treatment of claudication with dipyridamole and aspirin.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combin | 1986 |
36 other studies available for aspirin and Intermittent Claudication
| Article | Year |
|---|---|
[Principles of angiology in lower extremity arterial disease (LEAD)].
Topics: Amputation, Surgical; Ankle Brachial Index; Aspirin; Humans; Intermittent Claudication; Ischemia; Lo | 2020 |
Postexercise Ankle-Brachial Index Testing.
Topics: Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Exer | 2020 |
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cohort Studies; Drug Resistance; Female; Humans; Intermi | 2019 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
High Residual Collagen-Induced Platelet Reactivity Predicts Development of Restenosis in the Superficial Femoral Artery After Percutaneous Transluminal Angioplasty in Claudicant Patients.
Topics: Aged; Angiography; Angioplasty; Aspirin; Blood Platelets; Collagen; Female; Femoral Artery; Hemodyna | 2016 |
Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Drug Resistance; Female; Humans; Intermittent | 2016 |
Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.
Topics: Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Critical Illness; Drug Therapy, Combinati | 2016 |
Taking PET for a walk - an unusual cause of bilateral leg claudication.
Topics: Alendronate; Anti-Inflammatory Agents; Aspirin; Drug Therapy, Combination; Female; Giant Cell Arteri | 2010 |
Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study.
Topics: Analysis of Variance; Arteriosclerosis Obliterans; Aspirin; Blood Flow Velocity; Exercise; Female; H | 2010 |
[Percutaneous, endovascular treatment of innominate artery lesions is a safe and effective procedure].
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Brachiocephalic Tr | 2011 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions.
Topics: Aged; Amputation, Surgical; Aspirin; Blue Cross Blue Shield Insurance Plans; Chi-Square Distribution | 2012 |
[Peripheral arterial occlusive disease. Symptoms, basic diagnosis and staged therapy].
Topics: Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Exercise; Humans; | 2002 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Antiphospholipid syndrome in a child: an insight into the pathology, identification, and means of cure.
Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Arterial Occlusive Diseases; | 2004 |
Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; Case-Control Studies; Exercise Test; Female; Humans; | 2005 |
Variability in responsiveness to clopidogrel in patients with intermittent claudication.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Int | 2006 |
Point of care testing of aspirin resistance in patients with vascular disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery, Internal; | 2006 |
Prevention of transient endothelial dysfunction in acute exercise: a friendly fire?
Topics: Antioxidants; Aspirin; Endothelium, Vascular; Exercise; Humans; Intermittent Claudication; Lower Ext | 2007 |
Letter to the editor, re: Nylaende M, Abdelnoor M, Stranden E, Morken B, Sandbaek G, Risum O, et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patient
Topics: Angioplasty, Balloon; Aspirin; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Intermittent Cl | 2007 |
Increased platelet-monocyte aggregation in male claudicants with the Pl(A1/A2) polymorphism of Gp IIb/IIIa.
Topics: Aged; Aspirin; Blood Platelets; Female; Flow Cytometry; Gene Frequency; Genotype; Humans; Intermitte | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
[The effect of lysine acetylsalicylate on hemorrheological changes induced through ischemic exertion in patients with vascular disease].
Topics: Adult; Aged; Analgesics; Arterial Occlusive Diseases; Aspirin; beta-Thromboglobulin; Blood Viscosity | 1983 |
[Therapy of peripheral arterial occlusive diseases. Round table conference].
Topics: Alprostadil; Angioplasty, Balloon; Anti-Bacterial Agents; Anticoagulants; Arterial Occlusive Disease | 1983 |
Transluminal angioplasty of the iliac and femoral arteries: follow-up results without anticoagulation.
Topics: Adult; Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Female; Femoral Artery; Follow-Up Studie | 1981 |
Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Double-Blind Method; Female; Graft Survival; H | 1984 |
[Improvement of walking disability and conservative treatment. Guiding principles for drug treatment of chronic arterial occlusive disease (stage I and IIb)].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Dipyridamole; Fibrinolytic Agents; Humans; Int | 1984 |
Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte | 1981 |
[Arterial occlusion in cutis marmorata teleangiectatica congenita].
Topics: Adolescent; Angiography; Arterial Occlusive Diseases; Arteriovenous Malformations; Aspirin; Dose-Res | 1995 |
Extrapolation of trial results suggests that aspirin is useful in intermittent claudication.
Topics: Aspirin; Clinical Trials as Topic; Humans; Intermittent Claudication; Platelet Aggregation Inhibitor | 1998 |
Secondary prevention may help intermittent claudication.
Topics: Aged; Aspirin; Cholesterol; Coronary Disease; Fibrinolytic Agents; Follow-Up Studies; Humans; Interm | 2001 |
Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis.
Topics: Amputation, Surgical; Aspirin; Dextrans; Female; Heparin; Humans; Intermittent Claudication; Ischemi | 1988 |
[Medical treatment of peripheral arterial diseases].
Topics: Aspirin; Eicosapentaenoic Acid; Fibrinolytic Agents; Humans; Intermittent Claudication; Physical Exe | 1987 |
[The percutaneous recanalization of arterial obliterations with Dotter's catheter (Dotter's technic)].
Topics: Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Catheterization; Collateral Circulation; Femor | 1972 |